Clinical trial diversity: An opportunity for improved insight into the determinants of variability in drug response-Reference-Cited by-同舟云学术

Clinical trial diversity: An opportunity for improved insight into the determinants of variability in drug response

Published:2022-02-17 Issue:6 Volume:88 Page:2700-2717
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Gross Annette S.¹²^ORCID,Harry Anya C.³,Clifton Christine S.¹,Della Pasqua Oscar⁴⁵^ORCID

Affiliation:

1. Clinical Pharmacology Modelling & Simulation, GlaxoSmithKline R&D Sydney NSW Australia

2. Sydney Pharmacy School, Faculty of Medicine and Health The University of Sydney Sydney NSW Australia

3. Global Demographics & Diversity, Global Clinical Sciences and Delivery GlaxoSmithKline R&D Upper Providence PA USA

4. Clinical Pharmacology Modelling & Simulation, GlaxoSmithKline R&D Brentford UK

5. Clinical Pharmacology & Therapeutics Group School of Pharmacy – University College London London UK

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15242

Reference105 articles.

1. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.ICH Harmonised Tripartite Guideline. ICH E5 (R1): Ethnic Factors in the Acceptability of Foreign Clinical Data.1998. Accessed August 5 2020.https://database.ich.org/sites/default/files/E5_R1__Guideline.pdf

2. International Council on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.ICH Harmonised Guidelines. General Principles for Planning and Design of Multi‐Regional Clinical Trials. ICH E17.2017. Accessed October 6 2020.https://database.ich.org/sites/default/files/E17EWG_Step4_2017_1116.pdf

3. Diversity in randomized clinical trials of depression: A 36-year review

4. Ten‐Year Trends in Enrollment of Women and Minorities in Pivotal Trials Supporting Recent US Food and Drug Administration Approval of Novel Cardiometabolic Drugs

5. Under‐representation of elderly in clinical trials: An analysis of the initial approval documents in the Food and Drug Administration database

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pragmatic solutions for optimizing oncology drug development trials;Comprehensive Precision Medicine;2024

2. Molnupiravir Revisited—Critical Assessment of Studies in Animal Models of COVID-19;Viruses;2023-10-25

3. Safety and effectiveness of intravenous CT-P13 in inflammatory arthritis: post-marketing surveillance study in Thailand;Immunotherapy;2023-10

4. Interethnic differences in drug response: projected impact of genetic variations in the Saudi population;Pharmacogenomics;2023-08

5. Measuring the diversity gap of cannabis clinical trial participants compared to people who report using cannabis;Scientific Reports;2023-06-16